FlowVax Ebola/Marburg

About Flow Pharma

Flow Pharma is a private, pre-clinical stage biotech focused on immunotherapy using its proprietary FlowVax platform. The platform utilizes AI-designed synthetic peptides encapsulated in precisely constructed microspheres to stimulate targeted cytotoxic T-lymphocyte (CTL) responses. Its lead programs target COVID-19 (FLOVID-20) and treatment-resistant cancers like triple-negative breast cancer, with all assets currently in pre-clinical or research stages pending FDA approval. The company emphasizes a scalable, room-temperature stable dry powder format suitable for inhalation or injection.

Therapeutic Areas